bluebird bio Appoints Dr James Mandell To Its Board Of Directors
Published: Jan 09, 2014
bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell, M.D. has joined the company’s board of directors. In addition, bluebird bio announced that Axel Polack, Ph.D., general partner at TVM Capital Partners, has stepped down from the board.
Help employers find you! Check out all the jobs and post your resume.